Differences in the fitness of two diverse wild-type human immunodeficiency virus type 1 isolates are related to the efficiency of cell binding and entry.
about
Selective expansion of viral variants following experimental transmission of a reconstituted feline immunodeficiency virus quasispeciesHIV-1 Env C2-V4 diversification in a slow-progressor infant reveals a flat but rugged fitness landscapeDefining the fitness of HIV-1 isolates with dual/mixed co-receptor usageAppreciating HIV type 1 diversity: subtype differences in Env.Comparative biochemical analysis of recombinant reverse transcriptase enzymes of HIV-1 subtype B and subtype C.A single-residue change in the HIV-1 V3 loop associated with maraviroc resistance impairs CCR5 binding affinity while increasing replicative capacity.Male circumcision for prevention of HIV transmission: what the new data mean for HIV prevention in the United StatesHIV replication capacity is an independent predictor of disease progression in persons with untreated chronic HIV infection.HIV-1 Transmission, Replication Fitness and Disease Progression.Comparative analysis of the fusion efficiency elicited by the envelope glycoprotein V1-V5 regions derived from human immunodeficiency virus type 1 transmitted perinatally.The replicative fitness of primary human immunodeficiency virus type 1 (HIV-1) group M, HIV-1 group O, and HIV-2 isolates.Distinct HIV-1 entry phenotypes are associated with transmission, subtype specificity, and resistance to broadly neutralizing antibodies.Influence of Gag-protease-mediated replication capacity on disease progression in individuals recently infected with HIV-1 subtype C.Decreased infectivity of a neutralization-resistant equine infectious anemia virus variant can be overcome by efficient cell-to-cell spread.HIV-1 clinical isolates resistant to CCR5 antagonists exhibit delayed entry kinetics that are corrected in the presence of drugHIV-1 antiretroviral drug therapy.Vicriviroc resistance decay and relative replicative fitness in HIV-1 clinical isolates under sequential drug selection pressures.CCR5 Expression Levels in HIV-Uninfected Women Receiving Hormonal Contraception.Role of HIV-1 subtype C envelope V3 to V5 regions in viral entry, coreceptor utilization and replication efficiency in primary T-lymphocytes and monocyte-derived macrophages.Affinofile profiling: how efficiency of CD4/CCR5 usage impacts the biological and pathogenic phenotype of HIVMucosal tissue tropism and dissemination of HIV-1 subtype B acute envelope-expressing chimeric virusShort Communication: A Recombinant Variant with Increased Envelope Entry Efficiency Emerged During Early Infection of an HIV-1 Subtype C Dual Infected Rapid ProgressorClinical significance of human immunodeficiency virus type 1 replication fitness.The human immunodeficiency virus type 1 envelope confers higher rates of replicative fitness to perinatally transmitted viruses than to nontransmitted virusesMultifaceted mechanisms of HIV inhibition and resistance to CCR5 inhibitors PSC-RANTES and Maraviroc.HLA-associated alterations in replication capacity of chimeric NL4-3 viruses carrying gag-protease from elite controllers of human immunodeficiency virus type 1.CCR5- and CXCR4-tropic subtype C human immunodeficiency virus type 1 isolates have a lower level of pathogenic fitness than other dominant group M subtypes: implications for the epidemic.Selection of a simian-human immunodeficiency virus strain resistant to a vaginal microbicide in macaques.Human immunodeficiency virus type 1 V1-to-V5 envelope variants from the chronic phase of infection use CCR5 and fuse more efficiently than those from early after infection.A quantitative affinity-profiling system that reveals distinct CD4/CCR5 usage patterns among human immunodeficiency virus type 1 and simian immunodeficiency virus strainsInfection of rhesus macaques with a pool of simian immunodeficiency virus with the envelope genes from acute HIV-1 infections.Infecting HIV-1 Subtype Predicts Disease Progression in Women of Sub-Saharan Africa.HIV-1 Entry, Inhibitors, and ResistanceThe virus-receptor interaction in the replication of feline immunodeficiency virus (FIV).The high cost of fidelity.Subtype-Specific Differences in Gag-Protease-Driven Replication Capacity Are Consistent with Intersubtype Differences in HIV-1 Disease Progression.In vitro functional assessment of natural HIV-1 group M Vpu sequences using a universal priming approach.Vicriviroc: a CCR5 antagonist for treatment-experienced patients with HIV-1 infection.Natural variation in the V3 crown of human immunodeficiency virus type 1 affects replicative fitness and entry inhibitor sensitivityPathogenic infection of Rhesus macaques by an evolving SIV-HIV derived from CCR5-using envelope genes of acute HIV-1 infections.
P2860
Q27318192-15B1543C-0159-4977-B923-B1AE1183B765Q28487168-E7075D77-0303-464D-841E-C478F17AEB1AQ30278577-B5426F56-A3BF-49E9-B9E7-467542FE7DBCQ30375834-DF5BF77B-993C-4881-8D07-54446480A62AQ30394627-C4B463C1-F018-4CC8-80F4-00BACEC7D0C0Q30654651-6BF893ED-4A29-49E5-863F-E44EEDCA38F7Q31120761-10B8F449-1B9A-4A28-8644-501810630302Q33721788-A89A464F-F750-4C49-A88E-7BA9D1EABBB8Q33758570-DACBE40E-73E2-44FD-B639-36801589A321Q33879282-EDFF9677-F7BA-4F1F-9F9D-0CCBC89BD30BQ33884059-2FB52D05-F7F2-4ED0-B016-0F2900B87B8FQ34503200-25B09E10-92AF-45CE-B15B-EFAFB4C2D689Q35076519-3868342A-0FBA-4E6E-8C41-2E8D105BD4BDQ35383268-7D28C111-D323-4AEC-979A-AAA4818B33B2Q35665842-C49C4E51-E779-45C2-BDE0-D60A5CB81FA6Q35853012-51BFD71D-AC95-47D8-B2F4-5C7ABD3CDFF3Q36086642-4EBB669B-8E7D-4307-8C5E-83FDF14B21BFQ36149013-6D0C6B56-6DFA-4380-A943-1CC214600256Q36409768-49087359-651E-42EB-A99E-5B40987A5550Q36466404-15E83E2C-B844-463D-AF16-90298CBB83B6Q36559660-15B9FC43-9584-49E7-BEAF-36B4D5D0DD66Q36656789-6E714063-7A36-41F7-BBA3-65AD66C7FE9DQ36969857-94280100-8753-4BF9-82A8-5BA609800601Q36974671-252D29E5-1413-484B-904E-801CD3DB89EEQ37026646-34BE255F-6EDB-44C4-994F-6092BFDA56AFQ37033250-4BD18B32-1A62-4D98-BE87-AE7FC767CB04Q37191866-7770A5AF-1D54-453A-91BF-8168FD08A64DQ37192119-DAEBB4FE-F075-4F79-8585-02872C9F1A8FQ37356028-649E2310-8F95-48E2-AB8D-8C80B9B8118CQ37410812-1FCD7DEE-A556-46CE-9A0B-9DB40270B9C5Q37442592-D125B855-5A15-4182-8E23-C2A912107DBAQ37604707-79234F6B-E53F-44CB-B012-99CEBF40D23FQ37945205-06CC6C1B-15EB-44D5-9B06-4579A6D2020CQ38132942-5EC1C37C-9FCF-4828-8D09-65350FBF2C45Q38158093-37D9B589-3EEC-4C78-8783-BCAEC0D65056Q38706845-B272FEE8-5C00-4F49-9FC7-A8578D94CB97Q38730130-C89B2235-3B4E-4ADF-9703-C9B6BAA239DFQ39154839-D72C0702-1D9E-4531-A763-F6C8610BCFC5Q39186710-C84333C0-1F1C-4DD7-802D-84AAC65A6336Q39305961-31183EEB-4CFB-4A90-AA20-FD645B0970E6
P2860
Differences in the fitness of two diverse wild-type human immunodeficiency virus type 1 isolates are related to the efficiency of cell binding and entry.
description
2005 nî lūn-bûn
@nan
2005 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Differences in the fitness of ...... ncy of cell binding and entry.
@ast
Differences in the fitness of ...... ncy of cell binding and entry.
@en
type
label
Differences in the fitness of ...... ncy of cell binding and entry.
@ast
Differences in the fitness of ...... ncy of cell binding and entry.
@en
prefLabel
Differences in the fitness of ...... ncy of cell binding and entry.
@ast
Differences in the fitness of ...... ncy of cell binding and entry.
@en
P2093
P2860
P1433
P1476
Differences in the fitness of ...... ncy of cell binding and entry.
@en
P2093
Andre J Marozsan
Awet Abraha
Dawn M Moore
Eric J Arts
Erika Fraundorf
Jacqueline D Reeves
Michael A Lobritz
P2860
P304
P356
10.1128/JVI.79.11.7121-7134.2005
P577
2005-06-01T00:00:00Z